Aref Al-Kali

List of Publications by Citations

210 papers	1,801 citations	23 h-index	38 g-index
220 ext. papers	2,424 ext. citations	4.5 avg, IF	4.46 L-index

#	Paper	IF	Citations
210	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. *Leukemia*, **2013**, 27, 1322-7	10.7	168
209	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10	10.7	151
208	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer*, **2016**, 122, 1871-9	6.4	86
207	A dynamic N-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. *Cell Research*, **2018**, 28, 1062-1076	24.7	83
206	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Advances*, **2018**, 2, 923-932	7.8	73
205	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. *JAMA Oncology*, **2017**, 3, 936-943	13.4	59
204	Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells. *Leukemia*, **2017**, 31, 1434-1442	10.7	46
203	Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. *British Journal of Haematology*, **2015**, 169, 77-80	4.5	44
202	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2019**, 134, 673-673	2.2	43
201	The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. *Journal of Hematology and Oncology*, **2015**, 8, 114	22.4	42
200	A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. *Oncotarget*, **2014**, 5, 5494-509	3.3	41
199	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematology,the*, **2020**, 7, e601-e612	14.6	41
198	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. *Blood Cancer Journal*, **2017**, 7, e592	7	40
197	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
196	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. *Leukemia*, **2015**, 29, 741-4	10.7	33
195	Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *Transplant Infectious Disease*, **2016**, 18, 913-920	2.7	30
194	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. *Blood*, **2020**, 136, 909-913	2.2	28

193	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. *American Journal of Hematology*, **2020**, 95, 1511-1521	7.1	28
192	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27
191	Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29	7	27
190	A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. *Leukemia*, **2018**, 32, 865-873	10.7	26
189	Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. *Blood Cancer Journal*, **2017**, 7, e607	7	26
188	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. *Blood Cancer Journal*, **2016**, 6, e405	7	24
187	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. *American Journal of Hematology*, **2013**, 88, 365-9	7.1	22
186	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1431-1439	4.7	18
185	Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia. *Clinical Cancer Research*, **2017**, 23, 6254-6266	12.9	18
184	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Leukemia and Lymphoma*, **2017**, 58, 872-881	1.9	18
183	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. *American Journal of Hematology*, **2021**, 96, 781-789	7.1	17
182	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661	10.7	17
181	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. *Blood Cancer Journal*, **2016**, 6, e414	7	16
180	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 546-9	2	15
179	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. *Blood Cancer Journal*, **2017**, 7, e550	7	14
178	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. *Leukemia*, **2015**, 29, 498-500	10.7	14
177	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
176	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. *Blood Cancer Journal*, **2018**, 8, 82	7	14

175	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
174	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. *Leukemia*, **2021**, 35, 3542-3550	10.7	13
173	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. *American Journal of Hematology*, **2017**, 92, 866-871	7.1	12
172	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. *Transfusion*, **2016**, 56, 518-27	2.9	12
171	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. *Haematologica*, **2012**, 97, 235-40	6.6	12
170	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. *Blood*, **2019**, 134, 115-115	2.2	12
169	Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. *Oncotarget*, **2016**, 7, 36382-36394	3.3	12
168	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leukemia Research*, **2018**, 71, 60-62	2.7	11
167	Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. *International Journal of Cancer*, **2016**, 138, 1545-53	7.5	11
166	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. *Blood Cancer Journal*, **2021**, 11, 49	7	11
165	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. *Leukemia and Lymphoma*, **2017**, 58, 2588-2597	1.9	10
164	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38	6.4	10
163	Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. *Nature Communications*, **2019**, 10, 5051	17.4	10
162	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. *Blood Cancer Journal*, **2013**, 3, e122	7	10
161	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. *Systematic Reviews*, **2018**, 7, 144	3	10
160	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. *British Journal of Haematology*, **2019**, 187, e51-e54	4.5	9
159	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. *Leukemia and Lymphoma*, **2018**, 59, 2737-2739	1.9	8
158	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. *Leukemia and Lymphoma*, **2019**, 60, 559-561	1.9	8

157	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. *Mayo Clinic Proceedings*, **2019**, 94, 1467-1474	6.4	8
156	Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. *Leukemia Research*, **2015**, 39, 1207-1207	2.7	7
155	A population-based study of chronic neutrophilic leukemia in the United States. *Blood Cancer Journal*, **2020**, 10, 68	7	7
154	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. *American Journal of Hematology*, **2020**, 95, E203-E208	7.1	7
153	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2020**, 10, 121	7	7
152	Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults. *Leukemia*, **2016**, 30, 1177-80	10.7	6
151	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e39-41	2	6
150	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. *Modern Pathology*, **2020**, 33, 334-343	9.8	6
149	HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia. *ACS Applied Materials & Interfaces*, **2018**, 10, 14454-14462	9.5	5
148	Etiologies of Extreme Thrombocytosis: A Contemporary Series. *Mayo Clinic Proceedings*, **2019**, 94, 1542-1550	6.4	5
147	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. *Blood*, **2016**, 128, 339-339	2.2	5
146	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
145	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. *Leukemia and Lymphoma*, **2019**, 60, 990-999	1.9	5
144	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *British Journal of Haematology*, **2020**, 189, e104-e108	4.5	4
143	Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after CLAG-M vs. IMECO *Leukemia Research*, **2020**, 90, 106300	2.7	4
142	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1754-1758	4.7	4
141	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1714-5	1.9	4
140	Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. *Blood*, **2013**, 122, 2745-2745	2.2	4

139	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. *Blood*, **2016**, 128, 2799-2799	2.2	4
138	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leukemia Research*, **2016**, 50, 112-115	2.7	4
137	Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.. *American Journal of Hematology*, **2022**,	7.1	3
136	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. *Blood*, **2018**, 132, 437-437	2.2	3
135	A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2019**, 134, 4234-4234	2.2	3
134	Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding. *Blood*, **2012**, 120, 4930-4930	2.2	3
133	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. *Blood*, **2015**, 126, 55-55	2.2	3
132	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. *British Journal of Haematology*, **2021**,	4.5	3
131	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA □ venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111	7.1	3
130	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. *Blood Cancer Journal*, **2021**, 11, 43	7	3
129	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278	7.8	3
128	The 2016 revised World Health Organization definition of myelodysplastic syndrome with isolated del(5q): prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60	4.5	2
127	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. *Leukemia and Lymphoma*, **2019**, 60, 2483-2487	1.9	2
126	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. *American Journal of Hematology*, **2020**, 95, E257	7.1	2
125	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. *Oncotarget*, **2017**, 8, 94569-94579	3.3	2
124	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. *American Journal of Hematology*, **2018**, 93, E355-E357	7.1	2
123	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**,	7.1	2
122	Comparative Analysis of Azacitidine and Decitabine in Myelodysplastic Syndromes: A Systematic Review and Network Meta-Analysis. *Blood*, **2015**, 126, 1692-1692	2.2	2

121	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. *Blood*, **2015**, 126, 5234-5234	2.2	2
120	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. *Blood*, **2021**, 138, 219-219	2.2	2
119	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2018**, 132, 2722-2722	2.2	2
118	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
117	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. *Annals of Hematology*, **2020**, 99, 2119-2124	3	2
116	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
115	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. *American Journal of Clinical Pathology*, **2021**, 156, 679-690	1.9	2
114	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. *Annals of Hematology*, **2019**, 98, 331-337	3	2
113	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. *Blood and Lymphatic Cancer: Targets and Therapy*, **2021**, 11, 1-9	2.6	2
112	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404	7.1	2
111	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. *American Journal of Hematology*, **2021**, 96, E433-E436	7.1	2
110	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. *American Journal of Hematology*, **2022**,	7.1	2
109	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. *British Journal of Haematology*,	4.5	2
108	Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1582-1587	4.7	1
107	Leukemic Polyradiculopathy Due to Blastic Plasmacytoid Dendritic Cell Neoplasm. *JAMA Neurology*, **2015**, 72, 938-9	17.2	1
106	Characteristics of patients with myelodysplastic syndrome with balanced translocations. *British Journal of Haematology*, **2020**, 190, 244-248	4.5	1
105	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. *Annals of Hematology*, **2020**, 99, 513-518	3	1
104	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians survey. *American Journal of Hematology*, **2017**, 92, E626-E627	7.1	1

103	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. *Blood Cancer Journal*, **2022**, 12, 7	7	1
102	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
101	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
100	Erythrocytosis associated with (), (), or mutations: The Mayo Clinic experience.. *Haematologica*, **2022**,	6.6	1
99	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. *Blood*, **2019**, 134, 4560-4560	2.2	1
98	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). *Blood*, **2019**, 134, 3015-3015	2.2	1
97	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. *Blood*, **2020**, 136, 39-40	2.2	1
96	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. *Blood*, **2020**, 136, 31-32	2.2	1
95	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. *Blood*, **2013**, 122, 4049-4049	2.2	1
94	Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. *Blood*, **2014**, 124, 3264-3264	2.2	1
93	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. *Blood*, **2018**, 132, 5440-5440	2.2	1
92	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). *Blood*, **2019**, 134, 4182-4182	2.2	1
91	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 1476-1476	2.2	1
90	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. *Blood*, **2013**, 122, 3873-3873	2.2	1
89	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. *Blood Cancer Journal*, **2021**, 11, 47	7	1
88	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46	7	1
87	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. *British Journal of Haematology*, **2021**, 195, 133-137	4.5	1
86	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. *American Journal of Hematology*, **2021**, 96, E362-E367	7.1	1

85	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E398-E401	7.1	1
84	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416	4.5	1
83	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
82	R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.. *Frontiers in Oncology*, **2022**, 12, 849376	5.3	1
81	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. *American Journal of Hematology*, **2022**,	7.1	1
80	Deep neural network for cell type differentiation in myelodysplastic syndrome diagnosis performs similarly when trained on compensated or uncompensated data **2022**,		1
79	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. *Blood Cancer Journal*, **2022**, 12, 55	7	1
78	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. *Anticancer Research*, **2020**, 40, 3883-3888	2.3	0
77	Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 229-232	1.9	0
76	Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. *Blood*, **2020**, 136, 5-7	2.2	0
75	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0
74	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. *Blood*, **2021**, 138, 3657-3657	2.2	0
73	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368	2.2	0
72	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. *Blood*, **2021**, 138, 2158-2158	2.2	0
71	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. *American Journal of Hematology*, **2021**, 97, E62	7.1	0
70	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. *Blood*, **2021**, 138, 3691-3691	2.2	0
69	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. *Blood*, **2021**, 138, 3693-3693	2.2	0
68	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. *Blood*, **2021**, 138, 1517-1517	2.2	0

67	The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. *Blood*, **2019**, 134, 4249-4249	2.2	0
66	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. *Blood Cancer Journal*, **2021**, 11, 122	7	0
65	An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23. *Hypoxia (Auckland, N Z)*, **2019**, 7, 81-86	2.1	0
64	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leukemia and Lymphoma*, **2021**, 1-6	1.9	0
63	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL).. *Blood Cancer Journal*, **2022**, 12, 30	7	0
62	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. *American Journal of Hematology*, **2022**,	7.1	0
61	Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.. *American Journal of Ophthalmology Case Reports*, **2022**, 26, 101554	1.3	0
60	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E144-E146	7.1	
59	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. *International Journal of Hematology*, **2016**, 103, 409-15	2.3	
58	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leukemia and Lymphoma*, **2019**, 60, 246-249	1.9	
57	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. *Blood*, **2020**, 136, 26-27	2.2	
56	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. *Blood*, **2020**, 136, 44-44	2.2	
55	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. *Blood*, **2020**, 136, 34-35	2.2	
54	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. *Blood*, **2020**, 136, 43-44	2.2	
53	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. *Blood*, **2020**, 136, 35-36	2.2	
52	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. *Blood*, **2020**, 136, 30-31	2.2	
51	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. *Blood Cancer Journal*, **2022**, 12, 12	7	
50	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. *Blood*, **2021**, 138, 3688-3688	2.2	

49	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. *Blood*, **2021**, 138, 36-36	2.2
48	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267	2.2
47	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 2592-2592	2.2
46	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 3684-3684	2.2
45	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). *Blood*, **2021**, 138, 1096-1096	2.2
44	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. *Blood*, **2018**, 132, 1443-1443	2.2
43	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. *Blood*, **2018**, 132, 5510-5510	2.2
42	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2
41	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. *Blood*, **2018**, 132, 4344-4344	2.2
40	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. *Blood*, **2018**, 132, 2658-2658	2.2
39	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. *Blood*, **2018**, 132, 2678-2678	2.2
38	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689	2.2
37	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. *Blood*, **2019**, 134, 3005-3005	2.2
36	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). *Blood*, **2019**, 134, 5441-5441	2.2
35	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. *Blood*, **2019**, 134, 5406-5406	2.2
34	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. *Blood*, **2019**, 134, 3863-3863	2.2
33	DNA Cytosine-Demethylating Agent 5-Aza-2′-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine. *Blood*, **2019**, 134, 2513-2513	2.2
32	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. *Blood*, **2019**, 134, 1710-1710	2.2

31	A Phase II of Combination D aunorubicin and Cytarabine (A ra-c) and Nilotinib (TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results. *Blood*, **2015**, 126, 3808-3808	2.2
30	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. *Blood*, **2015**, 126, 3730-3730	2.2
29	Impact of the Type of Treatment Facility on the Outcome of Acute Myeloid Leukemia in the Adolescents and Young Adults: A National Cancer Data Base (NCDB) Study from 2003-2011. *Blood*, **2015**, 126, 529-529	2.2
28	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. *Blood*, **2015**, 126, 5260-5260	2.2
27	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062	2.2
26	Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study. *Blood*, **2015**, 126, 5636-5636	2.2
25	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. *Blood*, **2015**, 126, 4980-4980	2.2
24	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. *Blood*, **2015**, 126, 2490-2490	2.2
23	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. *Blood*, **2015**, 126, 4910-4910	2.2
22	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875	2.2
21	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. *Blood*, **2015**, 126, 1401-1401	2.2
20	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 1913-1913	2.2
19	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. *Blood*, **2015**, 126, 3747-3747	2.2
18	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. *Blood*, **2015**, 126, 4993-4993	2.2
17	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. *Blood*, **2015**, 126, 5254-5254	2.2
16	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. *Blood*, **2015**, 126, 4370-4370	2.2
15	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. *Blood*, **2016**, 128, 1996-1996	2.2
14	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110	2.2

List of Publications

13	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. *Blood*, **2011**, 118, 3795-3795	2.2
12	Transferrin Saturation (TS) Is a Surrogate Marker for Iron Deficiency Anemia (IDA),. *Blood*, **2011**, 118, 3175-3175	2.2
11	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. *Blood*, **2012**, 120, 3555-3555	2.2
10	FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience.. *Blood*, **2012**, 120, 2525-2525	2.2
9	Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). *Blood*, **2012**, 120, 4804-4804	2.2
8	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. *Blood*, **2013**, 122, 1405-1405	2.2
7	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. *Blood*, **2013**, 122, 4048-4048	2.2
6	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955	2.2
5	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. *Blood*, **2013**, 122, 2098-2098	2.2
4	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. *Blood*, **2013**, 122, 5226-5226	2.2
3	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334	2.2
2	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. *Blood*, **2013**, 122, 5000-5000	2.2
1	In reply-Myelodysplastic Syndrome Over Time: A Comparative Analysis of Overall Outcome. *Mayo Clinic Proceedings*, **2019**, 94, 2594	6.4